NASDAQ:VCYT

Veracyte (VCYT) Stock Price, News & Analysis

Veracyte logo
$25.09 +0.05 (+0.19%)
Closing price 11/20/2026 03:59 PM Eastern
Extended Trading
$24.90 -0.19 (-0.75%)
As of 11/20/2026 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Veracyte Stock (NASDAQ:VCYT)

Advanced

Key Stats

Today's Range
$24.53
▼
$25.60
50-Day Range
$24.00
▼
$52.52
52-Week Range
$21.91
▼
$60.91
Volume
2.79 million shs
Average Volume
3.00 million shs
Market Capitalization
$2.02 billion
P/E Ratio
16.19
Dividend Yield
N/A
Price Target
$44.50
Consensus Rating
Hold

Company Overview

Veracyte, Inc. is a genomic diagnostics company that develops tests to help clinicians diagnose disease and guide treatment decisions, with a focus on cancer and other complex conditions. Its tests analyze biological samples to provide information that can help distinguish between conditions and assess disease risk.

The company’s portfolio includes Afirma for thyroid nodule assessment, Decipher for prostate cancer, Prosigna for breast cancer, and Percepta for lung cancer. Veracyte also offers Envisia, a genomic test that supports the diagnosis of idiopathic pulmonary fibrosis and other forms of interstitial lung disease.

Founded in 2008 and headquartered in South San Francisco, California, Veracyte serves clinicians and patients in the United States and makes certain products available in international markets. Marc Stapley is the company’s chief executive officer.

AI Generated. May Contain Errors.

Veracyte Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
66th Percentile Overall Score

VCYT MarketRank™: 
3.30412226584 of 5 stars

Veracyte scored higher than 66% of companies evaluated by MarketBeat, and ranked 238th out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Veracyte has received a consensus rating of Hold. The company's average rating score is 2.42, and is based on no strong buy ratings, 6 buy ratings, 5 hold ratings, and 1 sell rating.

  • Upside Potential

    Veracyte has a consensus price target of $44.50, representing about 77.4% upside from its current price of $25.09.

  • Amount of Analyst Coverage

    Veracyte has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Veracyte's stock forecast and price target.
  • Earnings Growth

    Earnings for Veracyte are expected to decrease by -13.43% in the coming year, from $1.34 to $1.16 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Veracyte is 16.19, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.19.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Veracyte is 16.19, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 32.56.

  • Price to Book Value per Share Ratio

    Veracyte has a P/B Ratio of 1.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    12.08% of the float of Veracyte has been sold short.
  • Short Interest Ratio / Days to Cover

    Veracyte has a short interest ratio ("days to cover") of 8.22.
  • Change versus previous month

    Short interest in Veracyte has recently decreased by 2.67%, indicating that investor sentiment is improving.
  • Dividend Yield

    Veracyte does not currently pay a dividend.

  • Dividend Growth

    Veracyte does not have a long track record of dividend growth.

  • News Sentiment

    Veracyte has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Veracyte this week, compared to 5 articles on an average week.
  • Search Interest

    Only 6 people have searched for VCYT on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Veracyte to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Veracyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,858,904.00 in company stock.

  • Percentage Held by Insiders

    1.60% of the stock of Veracyte is held by insiders.

  • Percentage Held by Institutions

    Veracyte has minimal institutional ownership at this time.

  • Read more about Veracyte's insider trading history.
Receive VCYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VCYT Stock News Headlines

Veracyte (NASDAQ:VCYT) Stock Gets Price Target Reduction from Stephens
Veracyte Earnings Call Highlights Growth and Caution
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
Veracyte: Solid Profits, Slowing Tests, And A Stock In Limbo
Veracyte (NASDAQ:VCYT) Stock Price Target Cut by Piper Sandler
See More Headlines

VCYT Stock Analysis - Frequently Asked Questions

Veracyte's stock was trading at $42.10 on January 1st, 2026. Since then, VCYT stock has decreased by 40.4% and is now trading at $25.0880.

Veracyte, Inc. (NASDAQ:VCYT) announced its earnings results on Wednesday, November, 4th. The biotechnology company reported $0.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.10. The company's revenue was up 15.1% on a year-over-year basis.
Read the conference call transcript
.

Veracyte subsidiaries include HalioDx Inc., Decipher Biosciences Inc., Allegro Diagnostics, Decipher Corp., Delight Merger Sub II LLC, Veracyte Global B.V., Veracyte International Corp., and Veracyte SAS.

Veracyte (VCYT) raised $70 million in an initial public offering (IPO) on Wednesday, October 30th 2013. The company issued 5,000,000 shares at a price of $13.00-$15.00 per share.

Top institutional investors of Veracyte include State Street Corp (6.86%), William Blair Investment Management LLC (3.37%), GW&K Investment Management LLC (3.00%) and Goldman Sachs Group Inc. (2.78%). Insiders that own company stock include Marc Stapley, Rebecca Chambers, Phillip G Febbo, Annie Mcguire, John Leite, Robert S Epstein, Jonathan Wygant, Jonathan Wygant, Muna Bhanji, Evan/ Fa Jones, Jens Holstein and Karin Eastham.
View institutional ownership trends
.

Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Veracyte investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Micron Technology (MU), Block (XYZ), Advanced Micro Devices (AMD), Tesla (TSLA) and Invitae (NVTA).

Company Calendar

Last Earnings
11/04/2026
Today
11/22/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:VCYT
CIK
1384101
Employees
755
Year Founded
2008

Price Target and Rating

High Price Target
$65.00
Low Price Target
$30.00
Potential Upside/Downside
+77.4%
Consensus Rating
Hold
Rating Score (0-4)
2.42
Research Coverage
12 Analysts

Profitability

EPS (Trailing Twelve Months)
$1.55
Trailing P/E Ratio
16.19
Forward P/E Ratio
21.63
P/E Growth
N/A
Net Income
$66.35 million
Net Margins
21.80%
Pretax Margin
20.33%
Return on Equity
8.99%
Return on Assets
8.34%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.56
Quick Ratio
5.25

Sales & Book Value

Annual Sales
$517.15 million
Price / Sales
3.91
Cash Flow
$1.49 per share
Price / Cash Flow
16.87
Book Value
$17.76 per share
Price / Book
1.41

Miscellaneous

Outstanding Shares
80,690,000
Free Float
79,404,000
Market Cap
$2.02 billion
Optionable
Optionable
Beta
1.98

Social Links

7 Stocks That Could Be Bigger Than Tesla, NVIDIA, and Google Cover

Could the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.

Get This Free Report

This page (NASDAQ:VCYT) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners